Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

International Parkinson and Movement Disorder Society
Main Content

neuroQWERTY

Target population: Patients with Parkinson's disease

Measures:  Tremor, Bradykinesia, Cognition 

Clinical support: Diagnostic, Monitoring, Prediction 

nQ is a computational biotechnology company that uses digital phenotyping through Artificial Intelligence-aided analysis of personal device interactions to develop digital biomarkers for neurodegenerative diseases, like Parkinson's disease (PD) and Alzheimer’s disease (AD) in early and newly diagnosed/untreated stages.

Early data from the AD trial has advanced to yield early and promising results measuring cognitive decline and delineating PD and AD symptomatology. In prodromal stages of neurodegenerative diseases such as PD, digital biomarkers offer possibility of detecting actual subclinical symptoms prior to traditional methods of assessing phenoconversion and in combination with biochemical markers which often predict disease risk but not timing. Some key advantages of our digital biomarkers include: 

  • (1) Continuous, longitudinal, remote, real world quantification of psychomotor symptoms
  • (2) Patients are not burdened with completing structured tasks or clinic visits for data collection. Patients use their personal devices as they normally would, and data is collected passively and transparently, often 24/7
  • (3) Patient privacy and security is ensured at each step of algorithm. Biomarkers perform even though content of what patients type on their personal devices kept confidential and secure. 



Languages: English, Spanish, with coming 2022 releases in German, Japanese 

Platforms: Desktop, Tablet, Mobile Phone (iPhone, Android, Other) 

User interfaces: No traditional interface; Passive data collection of keystroke and touchscreen interaction. 

Additional Features:

  • Unlimited maximum number of subjects
  • Able to generate a database
  • Joint ownership of input data (nQ retains de-identified data) 
  • Data stored in Amazon Web Services
  • Control data available
  • Support for usage/test-setting/analysis available. Additional cost
     

For more information:
Teresa Arroyo Gallego, PhD 
gallego@nq-medical.com 

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including mds.movementdisorders.org and mds.execinc.com. This cookie policy only covers the primary movementdisorders.org and mdscongress.org domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice